News >

BRCA Gene Does Not Predict Poor Prognosis in Patients With Breast Cancer

Beth Fand Incollingo @fandincollingo
Published: Tuesday, Jan 10, 2017

Diana Eccles, MB, ChB, MD, FRCP

Diana Eccles, MB, ChB, MD, FRCP

While mutations of the BRCA gene can increase a woman’s chances of developing breast and ovarian cancers, the presence of the gene made no difference in survival for women aged 40 years or younger who were diagnosed with early-stage breast cancer, according to a recent study that followed participants for approximately 8 years. These findings were presented at the 2016 San Antonio Breast Cancer Symposium in December.

A multivariate analysis, which took into account BRCA status along with all other known factors that could influence prognosis, showed the maximum survival benefit for BRCA carriers with triple-negative breast cancer (TNBC) emerging at 2 years, with survival becoming more similar between the carriers and non-carriers of the gene by 5 years.

According to the lead author of the study, Diana Eccles, MB, ChB, MD, FRCP, a professor of Cancer Genetics and head of the Cancer Sciences Academic Unit at the University of Southampton in England, these results are important because there is a commonly held misconception that carrying a BRCA mutation worsens the prognosis of a patient who develops breast cancer.

“The conclusion is that, if you’re a patient who’s told you’re a (BRCA) carrier and you don’t (want to immediately undergo) a bilateral mastectomy, it’s not an important part of your treatment,” she said. “You can (wait and) make that decision separately from your treatment.”

Moreover, for women in this population, having a prophylactic bilateral mastectomy did not improve the risk for cancer recurrence or death. Three percent of the study’s non-BRCA carriers who had TNBC and 15% of BRCA carriers with TNBC underwent preventive bilateral mastectomy in their first year after diagnosis. When they were removed from researchers’ calculations, the survival advantage of young BRCA carriers with TNBC jumped from 11% to 13%, Eccles said.

The findings came out of a prospective study of nearly 2759 women aged 40 years or younger who had early-stage, invasive breast cancer. The study compared outcomes of treatment using breast-conserving surgery or unilateral mastectomy plus standard chemotherapy — an anthracycline, combined in some cases with a taxane — in women who had a BRCA mutation compared with women who did not, Eccles said.

The study, known as POSH, or the Prospective study of Outcomes for Sporadic versus Hereditary breast cancer, recruited participants with breast cancer who were in the target age group from 126 oncology clinics starting in 2000 and ending in 2008. The patients represented a quarter of those across the U.K. who were eligible for the study, and so it was highly representative of that population. Nearly none of the patients knew their BRCA status when diagnosed with cancer. They were tested for BRCA mutations this year as part of the study, and 14% were found to be positive for either a BRCA1 or a BRCA2 mutation.

The study’s primary endpoint was overall survival, and a secondary endpoint was the length of time without a distant metastasis. In both of these areas, outcomes in BRCA-positive women were compared with those in BRCA-negative patients. The women were followed for a median 8.2 years.

The study found no difference in survival for BRCA carriers versus non-carriers in the whole cohort overall.

Within the study population, 19%, or 511 women, had TNBC. A univariate analysis of that group (excluding those who underwent prophylactic mastectomy), which analyzed the impact of BRCA status on survival, showed that, at 5 years, 85.64% of BRCA carriers were alive compared with 71.03% of non-BRCA carriers. At 10 years, 78.66% of BRCA carriers in this subgroup were alive, compared with 65.24% of non-BRCA carriers. A multivariate analysis, which took into account BRCA status along with all other known factors that could influence prognosis, showed the maximum survival benefit for BRCA carriers with TNBC peaking at 2 years, with survival advantage becoming more similar between the 2 groups by 5 years, Eccles said.

She cautioned, however, that the survival benefit for BRCA carriers is an idea suggested, but not proven, by the study. For the benefit to be considered statistically significant, she said, the study would have needed to include over 1116 patients with TNBC.

Eccles went on to explain that the results of the study highlight the notion that younger, BRCA-positive patients diagnosed with breast cancer can at least temporarily put off decisions about preventive bilateral mastectomy and rely on regular screening for recurrence instead.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication